Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | ADA | P00813 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869472 | 0.85 | GPR84 (0.35) | GPR84ADAKCNH2KDM4EHPGD | |
| SCHEMBL24359772 | 0.81 | GRM4 (0.34) | KDM4E | |
| SCHEMBL27814382 | 0.81 | TLR8 (0.46) | GPR84ADA | |
| SCHEMBL28841518 | 0.80 | DNM2 (0.36) | GPR84ADA | |
| SCHEMBL18879376 | 0.77 | KDM4E (0.43) | GPR84ADAKDM4EHPGDMEN1 | |
| SCHEMBL26489338 | 0.75 | TLR8 (0.34) | BDKRB2 | |
| SCHEMBL20072427 | 0.75 | FAAH (0.40) | GPR84ADASLC2A1FAAH | |
| SCHEMBL19261307 | 0.75 | KCNH2 (0.41) | GPR84ADAKCNH2KDM4EMEN1 | |
| SCHEMBL29316557 | 0.75 | KCNH2 (0.41) | GPR84ADAKCNH2KDM4EMEN1 | |
| SCHEMBL10340564 | 0.74 | ACACB (0.45) | KDM4ESLC2A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | GPR84 626/4885ADA 2533/4885KCNH2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.